Next, using lentiviral vectors expressing a short hairpin RNA targeting CHROMR, it was demonstrated that CHROMR downregulation could reverse rituximab resistance of DLBCL cells, through upregulation of CD20 levels [29]. This evidence concerns the gene CHROMR and diffuse large B-cell lymphoma.